se of Lasuna Kalpa in the management of Oligomenorrhea(Artavakshaya)
Phase 3
- Conditions
- Health Condition 1: N915- Oligomenorrhea, unspecified
- Registration Number
- CTRI/2024/03/064660
- Lead Sponsor
- Dr Aishwarya Katara
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age group 18 to 40 years
Interval between two menstrual cycles is greater than 35 days.
Duration of menstrual flow is two days or less.
Patients complaining of anartava, alpartava, and yonishool.
Patients of primary, secondary amenorrhea and dysmenorrhea.
PCOD with symptom of oligomenorrhea and hypomenorrhea.
Exclusion Criteria
Pregnant women, lactating mothers
Positive to venereal diseases
PCOD with menorrhagia
Patients having any pelvic palpable pathology
Any malignant growth
Patient having congenital anomalies
Patient having any known chronic systemic disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Decrease in interval between two menstrual cycle <br/ ><br>2. Increase in amount of menstrual flow <br/ ><br>3. Increase in time of menstrual period.Timepoint: 12 weeks <br/ ><br>The trial drug will be given for 3 months with anupana and follow up one month after cessation of medicine
- Secondary Outcome Measures
Name Time Method State of PCOD,Hypomenorrhea, & Dysmenorrhea & also in artavakshaya.Timepoint: After analysing all parameters the result will be assessed on thon the basis of symptomatic relief & improvement <br/ ><br>Partially improvement after 4 wee patient gets 40-60 percent relief in sign & symptoms <br/ ><br>Improvement after 8 weeks patient gets 60-80 percent relief in sign & symptoms <br/ ><br>Cured after 12 weeks patient gets 80-100 percent relief in sign & symptoms